Now speaking at Global Voices in Renal Oncology (VIRO) 2025 organized by OncoDaily: Dr. Axel Bex, Urologic Surgeon and Consultant Clinical Lead of the Specialist Center for Kidney Cancer at the Royal Free London NHS Foundation Trust, on the topic “Neoadjuvant Therapy: Current Evidence and Ongoing Trials”.
Dr. Bex explained that, unlike melanoma, lung, and breast cancer, no neoadjuvant therapy has yet achieved approval or practice-changing results in kidney cancer. Most trials to date have been small, single-arm studies using PD-1 inhibitors or TKI combinations, with endpoints often limited to primary tumor response rather than long-term survival. He highlighted the need for larger, better-designed trials with appropriate endpoints, optimal drug combinations, and longer treatment duration.
He also described efforts to build an international kidney cancer consortium to align strategies and improve trial design, similar to initiatives in melanoma. Reporting on his group’s study at the Netherlands Cancer Institute, Dr. Bex noted that careful patient selection and translational research are beginning to yield valuable insights, though significant work remains before neoadjuvant therapy becomes standard practice in RCC.
Join us in this conversation.